Agilent agreed an all‑cash acquisition of Biocare Medical for $950 million, expanding the company’s pathology product set with immunohistochemistry (IHC), in‑situ hybridization (ISH/FISH) assays and more than 300 specialized antibodies. The deal brings established reagents and assay workflows into Agilent’s diagnostics and pathology footprint, strengthening its capabilities in tissue‑based biomarker testing and companion diagnostics support. Agilent positioned the purchase as a strategic step to meet rising demand for pathology tools used in oncology diagnostics and research.